Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma

Figure 3 Effect of linc00675 knockdown on pancreatic ductal adenocarcinoma growth in vitro. A: Knockout efficiency of siRNA targeting Linc00675 was confirmed by quantitative real time-polymerase chain reaction in SW1990 and MIA PaCa-2 cell lines, ^cP < 0.001, NC vs siLINC00675, Student’s t-test; B: Effects of knockdown of linc00675 on the proliferation of SW1990 and MIA PaCa-2 cells were assessed with MTT assay; C: Cell cycle of SW1990 and MIA PaCa-2 was analyzed by flow cytometry 48 h after transfection; D: Effect of knockdown of linc00675 on percentage of cells in G1-G0, S, and G2-M phase was examined quantitatively, ^aP < 0.05, NC vs siLINC00675, Student’s t-test; E: Cells were untreated, or transfected with linc00675, then the expression of CyclinA, CDK2, CyclinE and CyclinD1 was detected by Western blot. Data are represented as the mean ± SD from three independent experiments.